TSX Exchange Symbol: RVX
Also participating at 28th Annual JP Morgan Healthcare conference
Biotech Showcase provides presenting companies an opportunity to present to an audience of investors and biopharmaceutical executives during the course of the industry's largest annual healthcare investor conference. In conjunction with this presentation Resverlogix will also be participating in the annual JP Morgan Healthcare conference, which is a separate event that is taking place at the
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the
This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with future financings, the success of research and development programs. Additionally, risks and uncertainties are discussed in detail in the
%SEDAR: 00019253E
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email: [email protected]; US Investor Relations: Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: (212) 966-3650, Email: [email protected]
Share this article